Companies › Biofrontera
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Feb 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BF-200 ALA (Ameluz®) 5-aminolevulinic acid (ALA) prodrug; converted to protoporphyrin IX (PPIX) for photodynami | PPIX | Phase 3 | Superficial Basal Cell Carcinoma; Locally Advanced Colorectal Carcinoma | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03573401 | BF-200 ALA (Ameluz®) | Phase 3 | Superficial Basal Cell Carcinoma | Oncology | Feb 2029 |
| NCT06307548 | BF-200 ALA (Ameluz®) | Phase 1 | Locally Advanced Colorectal Carcinoma | Oncology | Jun 2029 |
Cash of $5m on 2026-06-30; operating cash outflow about $4m a year; runway about 16 months at that burn, to Oct 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Lakefront Biotherapeutics GT Medical Technologies Suzhou Immunofoco Biotechnology CG Oncology GeoVax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.